

APPA

AMERICAN PSYCHOPATHOLOGICAL ASSOCIATION, INC.

1910-2020

PROGRAM

2020 ANNUAL
MEETING

MARCH 5-7, 2020
NEW YORK CITY

Substance Use, Substance Use Disorders:
Changing Concepts, Changing Patterns

appasn.org

2019-2020 APPA Council

Officers

Deborah S. Hasin, PhD
Columbia University
President

James Potash, MD
Johns Hopkins University
President Elect

Kathleen Merikangas, PhD
National Institute of Mental Health
Vice President

William S. Stone, PhD
Harvard Medical School
Secretary

Joshua Breslau, PhD, ScD
RAND Corporation
Treasurer

Helen Wilson, PhD
Stanford University
Membership Chair

Coordinator

Jo-Ann L. Donatelli, PhD
Brown University

Councilors

Raymond DePaulo, MD
Johns Hopkins University School of
Medicine

Stephen E. Gilman, ScD
Eunice Kennedy Shriver National Institute
of Child Health and Human Development

Michael J. Lyons, PhD
Boston University Past President

Susan L. Santangelo, ScD
Maine Medical Center

Speakers:

Amy Bohnert, PhD

Associate Professor; Co-director, Mental Health Innovation, Services and Outcomes Program, University of Michigan

Katherine Carroll, PhD

Kent Professor of Psychiatry; Director, Psychosocial Research on Addictions, Yale University

Jonathan Caulkins, PhD

Professor, Carnegie Mellon University

Magdalena Cerdá, PhD

Associate Professor; Director, Center for Opioid Epidemiology and Policy, New York University

Sandra Comer, PhD

Professor of Psychiatry; Director, Opioid Laboratory, Columbia University

Don Des Jarlais, PhD

Associate Director/Professor, CDUHR, NYU School of Global Public Health

Christiane Duarte, PhD

Lambert Professor of Psychiatry; Director, Child Mental Health Disparities Group, Columbia University

Debra Furr-Holden, PhD

Mott Endowed Professor; Director, Flint Center for Health Equity Solutions, Michigan State University

Joel Gelernter, MD

Foundations Fund Professor; Director, Division of Human Genetics, Yale University Department of Psychiatry

Jaimie Gradus PhD

Associate Professor, Epidemiology/Psychiatry, Boston University

Bridget Grant, PhD

Former Director, NIAAA Lab of Epidemiology

Margaret Haney, PhD

Professor of Psychiatry, Director, Cannabis Research Laboratory, Columbia University

Deborah Hasin, PhD

Professor of Epidemiology; Columbia University

Mary Heitzeg,

PhD, Associate Professor/Chair, University of Michigan

Katherine Keyes, PhD

Associate Professor of Epidemiology, Co-Director, Psychiatric Epi Training Program, Columbia University

Andrea King, PhD

Professor of Psychiatry, Director, Addiction Research Laboratory, University of Chicago

George Koob, PhD

NIAAA Director

Henry Kranzler, MD

Professor of Psychiatry; Director, Center for Studies of Addiction, University of Pennsylvania

John Krystal, MD

Chair, Yale University Department of Psychiatry

Joshua Lee, MD

Associate Professor; Director, ABAM Fellowship in Addiction Medicine, New York University

Philip May, PhD

Professor, Global Public Health, University of North Carolina

Speakers continued:

Robin Murray, MD

*Professor of Psychiatry (and former Dean),
Institute of Psychiatry, Kings College*

Mark Olfson, MD

*Professor of Psychiatry, Columbia
University; Co-Director, AHRQ Center for
Education & Research on Mental Health
Therapeutics*

Stephanie O'Malley, PhD

*Professor of Psychiatry; Director, Substance
Abuse Research Division, Yale University*

Richard Saitz, MD

*Professor and Chair, Community Health
Services, Boston University School of Public
Health*

Eric Strain, MD

*Professor and Executive Vice Chair for
Psychiatry, Johns Hopkins Bayview Medical
Center*

Rajita Sinha, PhD

*Foundations Fund Professor; Director, Yale
Interdisciplinary Stress Center, Yale
University Department of Psychiatry*

Nora Volkow, MD

NIDA Director

Sylia Wilson, PhD

University of Minnesota

Chairs & Discussants

Charles Branas, PhD

*Chair, Department of Epidemiology,
Mailman School of Public Health, Columbia
University*

Chairs & Discussants continued:

Alan Budney, PhD

*Professor, Geisel School of Medicine,
Dartmouth College*

Deborah Hasin, PhD

*Professor of Epidemiology; Columbia
University*

Jill Harkavy-Friedman, PhD

*Associate Professor of Clinical Psychology,
in Psychiatry, Columbia University;
American Foundation for Suicide Prevention*

Diana Martinez, MD

*Professor, Columbia University Department
of Psychiatry*

Silvia Martins, MD, MPH

*Associate Professor of Epidemiology,
Columbia University*

Edward Nunes, MD

*Professor of Psychiatry, Yale University;
NIDA National Advisory Council Member*

John Rotrosen, MD

*Professor, Department of Psychiatry, New
York University*

Oral Poster Presenters

Corinne Bart, BA

Temple University

Sidra Goldman-Mellor, PhD

University of California at Merced

Alexandra Restrepo, MD, MSc

Columbia University

Vitor Tardelli, MD

Universidade Federal de Sao Paulo

Acknowledgements

Educational Grant

Amedco and the American Psychopathological Association would like to acknowledge the generosity of the following company whose unrestricted educational grant has contributed to the overall quality of the meeting:

Alkermes, Inc.

Donors

The American Psychopathological Association is extremely grateful to the following generous donors:

Institutional Donors

Columbia University, Department of Psychiatry

American Foundation for Suicide Prevention

Harvard Program in Psychiatric Epidemiology and Biostatistics

Individual Donors

Joshua Breslau	Michael Lyons
Evelyn Bromet	Kathleen Merikangas
Pamela Collins	Brittany Newman
William Coryell	Seth Prins
Francine Cournos	Tarek Rajji
John de Figueiredo	Susan Santangelo
Cristiane Duarte	Russell Schutt
Stephen Gilman	Patrick Shrout
Brianna Harney-Delehanty	Andrew Skodol, II
Deborah Hasin	William Stone
Van Lewis King, Jr.	Rudolf Uher
Maria Kovacs	Helen Wilson
Collins Lewis	

Donations toward the APPA Distinguished Fellow Memorial Award

In the past year, APPA Council established the APPA Distinguished Fellow Memorial Award to honor the memory of deceased APPA fellows through the establishment of an award in their name. The award will be established through a donation to the APPA meeting a minimum amount of \$2,000. Once the award is established, additional donations can be made to enhance the award over time. The list of APPA Distinguished Fellows will be published on the APPA web site and in each year's meeting program. APPA hopes that the close colleagues or relatives of deceased APPA members will lead the charge in soliciting donations in their memory.

The award will have the dual purpose of supporting meeting attendance by early career investigators and building the APPA endowment. The allocation of funds to these two purposes will be determined annually by the APPA council.

APPA recognizes generous donations by the individuals named below to establish the APPA Distinguished Fellow Memorial Award in memory of *Larry Seidman, PhD*:

Stephen Buka	Michael Lyons
Stephen Gilman	William Stone
William Kremen	Russell Schutt

Distinguished Fellow Memorial Award

The American Psychopathological Association is proud to announce the following recipients of the 2020 APPA Distinguished Fellow Memorial Award:

Barrett Montgomery, Michigan State University

The American Psychopathological Association is extremely grateful to the following:

Non-Council members who reviewed abstracts

Jo-Ann Donatelli	Ruth McKenzie
Akhgar Ghassabian	Diana Paksarian
Wendy Ingram	Line Jee Hartmann Rasmussen
Heather Lee	Emily Smail

Organization and conduction of the Wednesday Training Program Workshop

Jim Anthony and Nehal Vadham

Exhibitor

The Journal of Studies on Alcohol and Drugs

Student Participation Supporter

We acknowledge the generous support provided by the Department of Epidemiology at the Mailman School of Public Health and the Division of Epidemiology in the NYU Department of Population Health to support student participation in the APPA meeting.

Hamilton Awardees and Presidents of APPA

1910-11 Morton Prince	1958 Leslie B. Hohman	1991 Katherine A. Halmi
1912 Adolf Meyer	1959 Harry C. Solomon	1992 Elliot S. Gershon
1913 James T. Putnam	1960 David Wechsler	1993 C. Robert Cloninger
1914-15 Alfred R. Allen	1961 William Horsely Gantt	1994 Bruce P. Dohrenwend
1916-17 Adolf Meyer	1962 Laretta Bender	1995 Leonard Heston
1918 Smith Ely Jelliffe	1963 D. Ewen Cameron	1996 David Janowsky
1921 William A. White	1964 Jerome D. Frank	1997 Ellen Frank
1922 John T. MacCurdy	1965 Franz J. Kallmann	1998 Judith Rapoport
1923-24 L. Pierce Clark	1966 Seymour S. Kety	1999 Myrna M. Weissman
1925 Albert M. Barrett	1967 Bernard C. Glueck, Jr.	2000 John E. Helzer
1927 Sanger Brown II	1968 Benjamin Pasamanick	2001 Nina Schooler
1928-29 Ross McChapman	1969 Joel Elkes	2002 Jack Gorman
1930-31 William Healy	1970 Fritz A. Freyhan	2003 Charles Zorumski
1932 J. Ramsey Hunt	1971 Milton Greenblatt	2004 William W. Eaton
1933-34 Edward J. Kempf	1972 Alfred Freedman	2005 Ming Tsuang
1935-37 Nolan D.C. Lewis	1973 Henry Brill	2006 J. Raymond DePaulo, Jr.
1938 Samuel W. Hamilton	1974 Max Fink	2007 James J. Hudziak
1939 Abraham Myerson	1975 Charles Shagass	2008 Patrick E. Shrout
1940 Douglas A. Thom	1976 Arnold J. Friedhoff	2009 Darrel A. Regier
1941-42 Roscoe W. Hall	1977 George Winokur	2010 Linda B. Cottler
1943-44 Frederick L. Wells	1978 Gerald L. Klerman	2011 Cathy Spatz Widom
1945 Bernard Glueck	1979 Jonathan O. Cole	2012 Ezra Susser
1946 Robert P. Knight	1980 Donald F. Klein	2013 Evelyn J. Bromet
1947 Frederick L. Wells	1981 Paula J. Clayton	2014 Jeffrey A. Leiberan
1948 Donald J. MacPherson	1982 Samuel B. Guze	2015 Carol S. North
1949 Paul Hoch	1983 Robert L. Spitzer	2016 Thomas G. Schulze
1950 William B. Terhune	1984 Murray Alpert	2017 Andrew E. Skodol
1951 Lauren H. Smith	1985 James E. Barrett	2018 E. Jane Costello
1952 Joseph Zubin	1986 Robert M. Rose	2019 Michael J. Lyons
1953 Clarence R. Oberndorf	1987 David L. Dunner	2020 Deborah S. Hasin
1954-55 David McK. Rioch	1988 Lee N. Robins	2021 James B. Potash
1956 Oaskar Diethelm	1989 Bernard J. Carroll	
1957 Howard S. Liddell	1990 Nancy C. Andreasen	

AWARDS

The APPA has awards named for individuals who have made important contributions to the science of psychopathology. They are the Joseph Zubin Award, the Paul Hoch Award, the Eli Robins, Samuel Guze Award, and the Samuel W. Hamilton Award. For Hamilton awardees please see the listing of the President's of the APPA.

Previous Award Winners Since 1990

Year	Hoch Award	Year	Zubin Award	Year	Robins/Guze Award
1990	Arvid Carlsson	1992	George Winokur	2001	Frederick Cassidy
1991	Gerald Russell	1993	Albert Ellis	2002	Renee Cunningham Williams
1992	Robert C. Elston	1994	Alexander H. Leighton	2003	James Potash
1993	Lindon Eaves	1995	Paul R. McHugh	2004	David D. Rettew
1994	George Brown	1996	Myrna M. Weissman	2005	Karestan Koenen
1995	Stanley Prusiner	1996	Gerald L. Klerman	2006	Thomas G. Schulze
1996	Lester Luborsky	1997	Heinz Hafner	2007	Todd Lencz
1997	Ronald C. Kessler	1998	Barton Childs	2008	Catherine W. Striley
1998	Robin M. Murray	1999	David Kupfer	2009	Zubin Bhagwager
1999	John Rush	1999	Ellen Frank	2010	Valerie Harder
2000	Ming T. Tusang	2000	Samuel B. Guze	2011	Magdalena Cerdá
2001	Gerard Hogarty	2001	Robert Spitzer	2012	Monica Uddin
2002	Joseph E. LeDoux	2002	Bruce S. McEwen	2013	James Kirkbride
2003	Eric R. Kandel	2003	John W. Olney	2014	Carolyn Rodríguez
2004	George S. Alexopoulos	2004	Simon Wessely	2015	Armin Raznahan
2005	Jane M. Murphy	2005	Nikki Erlenmeyer-Kimling	2016	Katherine M. Keyes
2006	Paul McHugh	2006	David Botstein	2017	Nicholas R. Eaton
2007	Sir Michael Rutter	2007	John E. Helzer	2018	Natalie Slopen
2008	James M. Robins	2008	Bruce P. Dohrenwend	2019	Akghar Ghassabian
2009	Norman Sartorius	2009	David Shaffer	2020	Sylia Wilson
2010	Wilson M. Compton	2010	Ezra Susser		
2011	Naomi Breslau	2011	Patricia Cohen		
2012	Myron Hofer	2012	Zena Stein		
2013	Maria Kovacs	2013	Gabrielle A. Carlson		
2014	John H. Krystal	2014	Irving I. Gottesman		
2015	Kathleen Merikangas	2015	Jules Angst		
2016	Francis J. McMahon	2016	Paula J. Clayton		
2017	Robert F. Krueger	2017	John G. Gunderson		
2018	Terrie T. Moffitt	2018	Kenneth S. Kendler		
2018	Avshalom Caspi	2019	Evelyn J. Bromet		
2019	Stephen V. Faraone	2020	Bridget Grant		
2020	Mark Olfson				

In appreciation of extensive service on behalf of the APPA, we note the following awards:

Year	Student Leadership Award	Year	Special Service Awards
2001	Catina Meeks	2020	Jo-Ann Donatelli
2001	Gary Heiman	2020	Stephen Gilman
2020	David Fink	2020	Gary Heiman

SCIENTIFIC PROGRAM

Substance Use, Substance Use Disorders: Changing Concepts, Changing Patterns

The last two decades have seen enormous changes in public perceptions, laws and policies regarding substance use and substance use disorders. During this time, alcohol and drug use has increased markedly, especially opioids, marijuana and alcohol, leading to an opioid crisis and much debate about all of these substances. Research on substance use, its antecedents and consequences has seen substantial advances, from neurofunctioning to multi-level models of policy effects. At the same time, much remains to be learned. The 2020 APPA conference will present many of these areas, including many of the major studies are now underway that promise to provide important new information in the coming years. Major advances in behavioral and pharmacologic treatments have also been made, with more to be learned and done to better disseminate effective prevention efforts, and evidence-based treatments to those in need. The conference will also cover differences in important population subgroups (women, race/ethnic group), variation by life-cycle stage, stress, psychiatric comorbidity and suicide.

Speakers include NIDA and NIAAA directors, and internationally recognized leaders and experts in the areas to be presented. The conference will provide a lively interdisciplinary forum to discuss all of these issues, as well as considering important future directions.

Deborah S. Hasin, PhD, *President 2020*

Thursday, March 5, 2020

8:00 AM - 5:00 PM	Registration <i>Broadway Foyer and Atrium</i>
8:00 AM - 10:00 AM	Continental Breakfast <i>Broadway Foyer and Atrium</i>
9:00 AM – 10:15 AM	Session 1: The View From the National Institutes of Health <i>Broadway Ballroom Act I & II</i>
9:00 AM - 9:10 AM	Welcoming Remarks Deborah Hasin, PhD, <i>Professor of Epidemiology; Columbia University</i> <i>Chair</i>
9:10 AM - 9:35 AM	The View From NIAAA George Koob, PhD, <i>NIAAA Director</i>
9:35 AM - 10:00 AM	The View From NIDA Nora Volkow, MD, <i>NIDA Director</i>
10:00 AM - 10:15 AM	Discussion
10:15 AM - 10:30 AM	Break

10:30 AM – 12:00 PM **Session 2: Policy**
Broadway Ballroom Act I & II

Silvia Martins, MD, PhD, *Associate Professor of Epidemiology, Director, Center for Policy and Health Initiatives for Opioids and Other Substances (PHIOS), Columbia University*
Chair & Discussant

10:30 AM - 10:55 AM **How Can We Reverse the Tide of the Opioid Overdose Epidemic? Evidence on the Impact of Policy Solutions**
Magdalena Cerdá, PhD, *Associate Professor; Director, Center for Opioid Epidemiology and Policy, New York University*

10:55 AM - 11:20 AM **Injecting Drug Use, HIV and Syringe Service Programs; New Developments**
Don Des Jarlais, PhD, *Associate Director/Professor, CDUHR, NYU School of Global Public Health*

11:20 AM - 11:45 AM **Observations About Cannabis Legalization, Supply and Demand**
Jonathan Caulkins, PhD, *Professor, Carnegie Mellon University*

11:45 AM - 12:00 PM **Discussion**

12:00 PM - 12:20 PM **Oral Poster Presentations**
Broadway Ballroom Act I & II

12:00 PM - 12:05 PM **Parenting and Youth Cannabis Use**
Alexandra Restrepo, MD, MSc, *Columbia University*

12:05 PM - 12:10 PM **Prefrontal Responses to Monetary Rewards and Future Substance Use**
Corinne Bart, MA, *Temple University*

12:10 PM - 12:15 PM **Z-Drugs, Distress, Benzodiazepines, & Other Depressant Recreational Drugs**
Vitor Tardelli, MD, *Universidade Federal de Sao Paulo*

12:15 PM - 12:20 PM **Firearm Suicide Mortality in ED Patients**
Sidra Goldman-Mellor, PhD, *University of California at Merced*

12:20 PM - 1:20 PM **Lunch (On Your Own)**

1:20 PM – 2:50 PM **Session 3: Epidemiology**
Broadway Ballroom Act I & II

Charles Branas, PhD, *Chair, Department of Epidemiology, Mailman School of Public Health, Columbia University*
Chair & Discussant

1:20 PM - 1:45 PM **Age, Period, and Cohort Effects in Substance Use and Mental Health in the 21st Century**
Katherine Keyes, PhD, *Associate Professor of Epidemiology, Co-Director, Psychiatric Epi Training Program, Columbia University*

1:45 PM - 2:10 PM	Breaking the Cycle of Adversity: Intergenerational Processes and Substance Use Disorders <i>Christiane Duarte, PhD, Lambert Professor of Psychiatry; Director, Child Mental Health Disparities Group, Columbia University</i>
2:10 PM - 2:35 PM	Racial Inequity in Psychiatric and Substance Use Disorders Among African Americans <i>Debra Furr-Holden, PhD, Mott Endowed Professor; Director, Flint Center for Health Equity Solutions, Michigan State University</i>
2:35 PM - 2:50 PM	Discussion
2:50 PM - 3:15 PM	Presentation of the Hamilton Award Substance Use Disorders: Changing Concepts, Changing Trends <i>Deborah Hasin, PhD, Columbia University</i>
3:15 PM - 3:30 PM	Break
3:30 PM – 5:25 PM	Session 4: Neurofunctioning and Genetics <i>Broadway Ballroom Act I & II</i> <i>Diana Martinez, MD, Professor, Columbia University Department of Psychiatry Chair & Discussant</i>
3:30 PM - 3:55 PM	Glutamate and the Neurobiology of Human Alcoholism <i>John Krystal, MD, Chair, Yale University Department of Psychiatry</i>
3:55 PM - 4:20 PM	Gender, Stress, & Substance Use Disorders <i>Rajita Sinha, PhD, Foundations Fund Professor; Director, Yale Interdisciplinary Stress Center, Yale University Department of Psychiatry</i>
4:20 PM - 4:45 PM	Insights on the Genetics of Alcohol Use and Dependence From the Million Veteran Program <i>Joel Gelernter, MD, Foundations Fund Professor; Director, Division of Human Genetics, Yale University Department of Psychiatry</i>
4:45 PM - 5:10 PM	Adolescent Brain & Cognitive Development (ABCD) Study <i>Mary Heitzeg, PhD, Associate Professor/Chair, University of Michigan</i>
5:10 PM - 5:25 PM	Discussion
6:00 PM – 7:30 PM	Poster Session I <i>Broadway Ballroom Act III & IV</i>
Friday, March 6, 2020	
8:00 AM - 5:00 PM	Registration <i>Broadway Foyer and Atrium</i>

- 8:00 AM - 9:00 AM **Continental Breakfast**
Broadway Foyer and Atrium
- 8:00 AM – 9:30 AM** **Poster Session II**
Broadway Ballroom Act III & IV
- 9:30 AM – 10:40 AM** **Session 5: Measurement: Diagnosis, Outcomes**
Broadway Ballroom Act I & II
- Edward Nunes, MD, *Professor of Psychiatry, Columbia University*
Chair & Discussant
- 9:30 AM - 9:35 AM **Presentation of the Zubin Award**
Bridget Grant, PhD, *Former Director, NIAAA Lab of Epidemiology*
- 9:35 AM - 10:00 AM **Beyond Traditional Outcome Measures for SUD's**
Eric Strain, MD, *Professor/Director, Johns Hopkins University*
- 10:00 AM - 10:25 AM **Meaningful Clinical Trial Endpoints**
Stephanie O'Malley, PhD, *Professor of Psychiatry; Director, Substance Abuse Research Division, Yale University*
- 10:25 AM - 10:40 AM **Discussion**
- 10:40 AM - 10:55 AM **Break**
- 10:55 AM – 12:25 PM** **Session 6: Exposure Consequences I**
Broadway Ballroom Act I & II
- Jill Harkavy-Friedman, PhD, *Associate Professor of Clinical Psychology, in Psychiatry, Columbia University; American Foundation for Suicide Prevention*
Chair & Discussant
- 10:55 AM - 11:20 AM **Cannabis and Psychosis**
Robin Murray, MD, *Professor of Psychiatry (and former Dean), Institute of Psychiatry, Kings College London*
- 11:20 AM - 11:45 AM **Substance Use, Overdose and Suicide**
Amy Bohnert, PhD, *Associate Professor; Co-director, Mental Health Innovation, Services and Outcomes Program, University of Michigan*
- 11:45 AM - 12:10 PM **Predicting Suicide Among Persons With Substance Use Disorders in the Population of Denmark**
Jaimie Gradus PhD, *Associate Professor, Epidemiology/Psychiatry, Boston University*
- 12:10 PM - 12:25 PM **Discussion**
- 12:25 PM – 1:25 PM **APPA Annual Business Meeting (Open to All Attendees)**
Broadway Ballroom Act I & II
- 1:25 PM - 2:15 PM **Lunch (On Your Own)**

2:15 PM – 4:10 PM

Session 7: Exposure Consequences II

Broadway Ballroom Act I & II

Alan Budney, PhD, *Professor, Geisel School of Medicine, Dartmouth College
Chair & Discussant*

2:15 PM - 2:40 PM

Linking Maternal Risk Traits to Specific Child Diagnoses in Fetal Alcohol Spectrum Disorders (FASD)

Philip May, PhD, *Professor, Global Public Health, University of North Carolina*

2:40 PM - 3:05 PM

Alcohol Stimulating and Sedating Effects

Andrea King, PhD, *Professor of Psychiatry, Director, Addiction Research Laboratory,
University of Chicago*

3:05 PM - 3:30 PM

The Risks and Benefits of Naloxone Prescribing to Drug Users: A Randomized, Controlled Trial

Sandra Comer, PhD, *Professor of Psychiatry; Director, Opioid Laboratory, Columbia University*

3:30 PM - 3:55 PM

Cannabis Use Disorder: Current Perspectives

Margaret Haney, PhD, *Professor of Psychiatry, Director, Cannabis Research Laboratory, Columbia University*

3:55 PM - 4:10 PM

Discussion

4:10 PM - 4:25 PM

Break

4:25 PM - 4:50 PM

Presentation of the Hoch Award

Are the Opioid and Suicide Epidemics Linked?

Mark Olfson, MD, *Professor of Psychiatry, Columbia University; Co-Director, AHRQ Center for Education & Research on Mental Health Therapeutics*

4:50 PM - 5:00 PM

Discussion

Saturday, March 7, 2020

8:00 AM - 12:00 PM

Registration

Broadway Foyer and Atrium

8:00 AM - 10:00 AM

Continental Breakfast

Broadway Foyer and Atrium

8:00 AM – 9:00 AM

Early Career Investigators Round Table Breakfast

4th Floor, Room 407

9:00 AM - 9:30 AM

Presentation of the Robins-Guze Award

Broadway Ballroom Act I & II

Problematic Alcohol Use and Brain Structure and Functioning: Disentangling Cause From Consequence Using a Co-Twin Control Study Design

Sylia Wilson, PhD, *Assistant Professor, Institute of Child Development, University of Minnesota*

Poster Session I
Thursday, March 5, 2020, 6:00 PM – 7:30 pm

AUTHORS	TITLE	NUMBER
Askari M, Mauro, PM	The Relationship Between Co-Occurrence of Any Mental Illness and Substance Use Disorders and Perceived Behavioral Health Treatment Need, 2015-2017	1
Bennett EM, Goldstein NS, Parekh VK, Ruble AE, Purser R	Managing Opiate Overdose in the Outpatient Setting: A Scoping Review of Office Emergency Preparedness	2
Brooner RK, Kidorf M, Stoller K, Gandotra N	Using Community Pharmacies to Bring Methadone Treatment to Scale for Opioid Use Disorder: Process and Progress	3
Gutkind S, Starbird L, Murphy SM, Feaster D, Metsch L, Schackman BR	Cost of Hepatitis C Care Facilitation for HIV/Hepatitis C Co-Infected People Who Use Drugs	4
Huỳnh C, Rochette L, Pelletier É, Jutras-Aswad D, Fleury MJ, Kisely S, Lesage A	Prevalence Estimates of Mental Disorders in Individuals Diagnosed with Substance Related Disorders and Patterns of Mental Health Services Utilization Using the Quebec Integrated Chronic Disorders Surveillance System	5
Rehn-Mendoza, N	Treatment of Cannabis-Related Problems in the Nordic Countries	6
Villatoro A, DuPont-Reyes MJ, Pinedo M, Parra-Cardona R, Link BG	Preventing Stigma and Promoting Treatment for Substance Use Problems: A Research Agenda	7
Carson K, Babad S, Fairchild V, Barahmand U, Brown EJ, Nikulina V	Sexual Victimization Disclosure: A Cluster Analysis Approach to Understanding Victimization Experiences in Disclosers and Non-Disclosers	8
Fairchild VP, Walsh Carson K, Babad S, Zwilling A & Nikulina V	Differences in Young Adult Women Who Perpetrate Intimate Partner Violence	9
Fialk A	Wounded versus Non-Wounded Healers and Substance Abuse Treatment: Countertransference Considerations	10
Fox EC, Wilson HW	Baseline Substance Use in University Students Seeking Psychotherapy after Experiencing Sexual and Relationship Violence	11
Garrey SK, Li J, Pollari C, Martins SS, Brackbill R, Takemoto E	The Association Between PTSD Symptom Clusters and Opioid-Related Hospitalizations among World Trade Center Health Registry Enrollees	12
Russel J, Giesinger I, Takemoto E, Li J	Association Between Post-Traumatic Stress Disorder and Alcohol-Related Hospitalizations among World Trade Center Health Registry Enrollees	13
Tardelli VS, Fidalgo TM, Martins SS	Z-Drugs and Their Relationship with Psychological Distress, Benzodiazepines, and Depressant Recreational Drugs: A Cross-Sectional Analysis	14
Tineo K, Razak S, Carson KW, Babad S, Fairchild C, Robinson G, Kosuri M, Nikulina V	Non-Disclosure of Sexual Victimization: Qualitative and Quantitative Analysis of Themes Contributing to Non-Disclosure	15
Beesdo-Baum K, Venz J, Pieper L	DSM-5 Tobacco Use Disorder and Its Association with Sleep Disturbance: A Cross-Sectional Epidemiological Study Among Adolescents and Young Adults from Germany	16

Perlmutter AS, Segura LE, Martins SS	Does the Rate of Asthma Emergency Department Visits Depend on Electronic Smoking Device Availability in California Over Time?	17
Bruzelius E, Levy NL, Segura LE, Philbin MM, Nesoff ED, Mauro PM, Martins SS	Opioid-Related Emergency Department Visits in the United States Among Children and Adolescents by Urbanicity: 2007-2014	18
Prigerson HG, Avery J, Rao R, Maciejewski PK, Rogers M, Viola M, Kakarala S, Lichtenthal, WG	Enhancing & Mobilizing the Potential for Wellness & Emotional Resilience (EMPOWER): Applying a Mind-Body Approach to Assist Families in the Aftermath of an Opioid Overdose	19
Quintero G	Updated Revision about the Treatments for Opioid Use Disorders	20
Rouhani S, Park JN, Morales KB, Green TC, Sherman SG	Trends in Opioid Initiation in Baltimore, Boston and Providence	21
Chaim CH, Santana GL, Albertin PdV, Silveira CM, Viana MC, Andrade LH	Alcohol Use Patterns and Disorders Among Individuals with Personality Disorders in the Sao Paulo Metropolitan Area	22
Haeny AM, Krystal JH, O'Malley SO	Differences in the Associations Between Risk Factors for Alcohol Use Disorder and Alcohol-Use Related Outcomes Among Black and White Individuals	23
Knox J, Wall M, Scodes J, Witkiewitz K, Mann KF, Kranzler HR, Falk DE, Litten RZ, O'Malley SS, Anton RF, Hasin DS	Reduction in World Health Organization (WHO) Drinking Risk Levels and Cardiovascular Disease (CVD): 3-Year Follow-Up Results in the US General Population	24
Martins JS, Bartholow BD, Cooper ML	Heterogeneity in Psychological and Behavioral Domains Underlying the Risk for Alcohol Use Disorder	25
Ventura-Cots M, Watts AE, Cruz-Lemini M, Shah ND, Ndugga N, McCann P, Barritt 4th AS, Jain A, Ravi S, Fernandez-Carrillo C, Abralde JG, Altamirano J, Bataller R	Colder Weather and Fewer Sunlight Hours Increase Alcohol Consumption and Alcoholic Cirrhosis Worldwide	26
McKetta SC, Prins SJ, Bates LM, Platt JM, Keyes KM	US Trends in Binge Drinking by Gender, Work Status, and Work Prestige Among Adults in Midlife, 2006-2018	27
Pinedo M	The Impact of Immigration Enforcement Policies on the Alcohol and Drug Using Behaviors of US-Citizen Latinos	28
Goldman-Mellor SJ, Hall C, Bhat H	Firearm Suicide Mortality Among Emergency Department Patients: Associations with Patient Diagnosis and Demographic Factors	29
Kajeepeta S, Mauro PM, Prins SJ	Substance Use Disorder Mortality as a Feature of the Association Between County Jail Incarceration and County Mortality in the United States from 1987-2016	30
Marziali ME, McLinden T, Card KG, Closson K, Wang L, Trigg J, Salters K, Lima VD, Parashar S, Hogg RS	The Relationship Between Social Isolation and All-Cause Mortality Among People Living with HIV in British Columbia, Canada	31
Fink DS, Keyes KM, Branas CC, Gruenewald PJ, Cerda M, Hasin DM	Association Between Prescription Opioid Supply and Fatal Drug Poisonings in the United States	32
Rudolph KE, Kinnard EN, Goin DE, Rivera Aguirre AE, Feelemyer J, Fink D, Cerda M	The Relative Economy and Drug Overdose Deaths	33

Carise D	The Rising Rates of Cocaine and Amphetamine Use and Overdose Deaths: A Local and National Perspective	34
Gao W, Wilson T, Kassaye S, Weiser S, Weber K, Golub E, Adimora A, Lahiri C, Fischl M, Konkle-Parker D, Kempf MC	Associations Between Post-Traumatic Stress Disorder Symptoms and Residential Geographic Location for HIV-Positive Women and HIV-Negative Women	35
DuPont-Reyes MJ, Villatoro AP, Phelan JC, Painter K, Link BG	Estimating School Race/Ethnic Enrollment Effects on Student Mental Health: Density Versus Diversity as a Risk or Protective Factor	36
Gregoire VA, Vsevolozhskaya OA, Anthony JC	Neglected 'Survey Context Effects' in Psychiatric Epidemiology?	37
Harder VS, Plante TB, Varni SE, Murray K, Villanti A, Wolfson D, Fairfield K	Prescription Opioid Policy Changes Impact on Opioid Overdose and Related Adverse Effects	38
Harder VS, Plante TB, Koh I, Villanti A, Maruthi S, Rogers E, Fairfield K	Influence of Opioid Prescribing Policy Changes on Opioid Overdose and Related Hospital Use in Primary Care	39
Montgomery BM, Vsevolozhskaya O, Anthony JC	Testing an Epidemiologic Theory of Policy-Shaped Drug Use Onset Curves	40
Nesoff ED, Branas CC, Martins SS	The Impact of Neighborhood Characteristics on Traveling for Drug Use	41
Shover CL, Vest NA, Chen D, Stueber A	Cannabis Dispensaries Online Advertising about Opioid Use Disorder: First Stage Results from a Multi-State Mixed Methods Study in the Northeastern U.S.	42
Curreri AJ, Logue MW, McKenzie RE, Toomey R, Panizzon MS, Franz CE, Kremen WS, Reynolds CA, Lyons MJ	The Interaction Between Polygenic Risk for Neuroticism and Childhood Adversity in the Development of Emotional Disorders	43
Foote B, Cui L, Merikangas K	Familial Aggregation and Co-Aggregation of Social Anxiety Disorder and Comorbid Disorders in Family Study of Affective Spectrum Disorders	44
Ramey T, Keyser-Marcus L, Adams M, Thacker L, Moeller FG	Addiction Deep Phenotyping: NIDA Phenotyping Assessment Battery (NIDA PhAB) Feasibility and Validation Study	45
Moore AA, Hettema JM, Roberson-Nay R	The Effects of Sex and Age on the Heritability of Callous-Unemotional Traits	46
Stapp EK, Cui L, Guo W, Merikangas KR	Familial Aggregation and Co-Aggregation of Pain-Relation Conditions and Mood Disorders in Adults	47

Poster Session II
Friday, March 6, 2020, 8:00 AM – 9:30 AM

AUTHORS	TITLE	Number
Babad S, Carson KW, Zwilling A, Nikulina V	Still Single: Long-Term Impact of Childhood Physical and Sexual Abuse	1
Bonagura AG, Widom CS	Neglect, Sexual Abuse, and Psychiatric Disorders Increase Risk for Stalking	2
Grummitt, LR, Kelly, EV, Keyes, KM and Newton, NC	Pathways from Childhood Adversity to Substance Use in Young People: A Systemic Review of Targets for Prevention	3
Sussman TJ, Santaella-Tenorio J, Duarte CS, Wall MW, Ramos-Olagastí M, Suglia SF, Canino G, Bird H, Martins SS	Are Gender and Child Maltreatment Subtypes Related to Trajectories of Sensation Seeking?	4
Bruno R, Peacock A, Campbell G, Larance B, Lintzeris N, Nielsen S, Hall W, Cohen M, Degenhardt L	DSM-5 Opioid Use Disorder: Is It Consistent Among Chronic Pain Patients and People Who Inject Pharmaceutical Opioids?	5
Young M, Gretton M, Bruno R	Don't Touch That Drink! Making Serious Cognitive Testing More Engaging for Use in Substance Consumer Contexts	6
Carpenter RW, MacLean RR, Trull TJ	Momentary Opioid Craving and Physical Pain are Independently Associated with Prescribed Opioid Use in Patients with Chronic Pain in Daily Life	7
Gorfinkel LR, Simmons W, Stohl M, Hasin DS	How Does Opioid Use Change on Days Where Cannabis Is Consumed?	8
Precin P	Occupational Therapy Treatment Techniques for the Management of Pain Associated with Opioid Use Disorder	9
Muzumdar N, Shenoy A, Jacko AL, Vaschillo EG, Vaschillo B, Bates ME, Buckman JF	Daily Lifestyle Data Suggests Early Surges in First-Year College Drinking	10
Shenoy, Schubert, Mirza, Ford, Filipovic, Wankoff, Dienstag, Mohan, Im	Scoring Systems to Predict Relapse Risk in Alcohol Use Disorder Presenting for Liver Transplantation	11
Kuerbis, A, Shao S, Vadhan, N, Morgenstern, J.	Preliminary Efficacy of Motivational Interviewing on Problem Drinkers 55 and Older Compared to Younger Counterparts	12
Slade T, Swift W, Mewton L, Clay P, Tibbetts J, McCraw S, Upton E, Johnson P, Isik A, Kypri K, Lynskey M, Butterworth P	DSM-IV, DSM-5, ICD-10 and ICD-11 Alcohol Use Disorders in a Sample of Young Adult Regular Alcohol Users: Definition Matters	13
Vandivier A	The Growth of Spiritual Awareness Through AA Participation: A Phenomenological Study	14
Vest N, Humphreys KN	The Influence of Depression and Alcoholics' Anonymous Involvement on Alcohol Use Among Dual-Diagnosis Veterans: A Growth Mixture Model	15
Yung EC, Cassis T, Low NC	Coping Styles and Current Alcohol and Substance Misuse Among Mood Disorders	16

Doonan SM, Johnson JK	Risk and Protective Factors Associated with Cannabis Use in Massachusetts Youth	17
Joshi S, Patrick ME	Trends and Time-Varying Associations Between Attitudes of Marijuana Legalization and Marijuana Use Among US 12th Grade Students from 1976 to 2017	18
Levy NS, Mauro PM, Mauro CM, Martins SS	Evolution of the Perceived Risk and Availability of Marijuana in the United States, 2002-2014	19
Restrepo A, Keys K, Mauro P	The Association Between Cannabis Use and Parenting of Male and Female Adolescents Ages 12 to 17 Years	20
Schaefer JD, Hamdi NR, Wilson S, McGue M, Iacono WG	Associations Between Cannabis Use Disorder and Psychosocial Outcomes in Young Adulthood: A Longitudinal Co-Twin Control Study	21
Magalhães Silveira C, Castaldelli-Maia JM, Siu ER, Andrade L	Latent Class Analyses Subtypes of Cannabis Users and Associations with Differential Risk and Harm Outcomes: Results from the Sao Paulo Megacity Mental Health Survey	22
Berns AM, Levak S, Chen AC, Martins-Welch D, Morgenstern J, Vadhan NP	Sex Differences in Cannabis Users in the New York Metropolitan Area: A Community Survey	23
Diaz JE, Greene, ER, Philbin MM, Martins SS, Mauro PM	Sexual Identity Moderates the Association Between Substance Use Disorders and Suicidal Ideation Among Adults Who Use Substances	24
Lopez D, Paksarian D, Cui L, Merikangas KR	Familial Coaggregation of Chronotype and Suicide	25
Borota D, Nestadt PS	Characterizing Physician Suicides in the U.S. (2003-2015)	26
Nguyen JL, Shepard MD, Perepezko K, Pontone GM, Nestadt PS	Suicide Among Maryland Decedents with Parkinson's Disease	27
Polanco-Roman L, Ortin A, Corbeil T, Alvarez K, Wall M, Gould M, Alegria M, Bird H, Canino G, Duarte CS	Parental Suicidal Behaviors and Substance Use in Early Adolescents: Clarifying Early Markers of Suicide Risk in Young Adulthood	28
Segura LE, Levy NS, Perlmutter AS, Santaella-Tenorio J, Martins SS	The Association Between Prescription Opioid Misuse and Suicidality in United States Adolescents: NSDUH 2015-2017	29
Cuthbert KN, Logue M, Reynolds C, Toomey R, McKenzie R, Kremen WS, Franz CE, Panizzon MS, Ditmars H, Vandiver R, Lyons MJ	Genetic and Environmental Influences on Alcohol Consumption Over 30 Years in Vietnam-Era Veteran Twins	30
Salvatore JE, Larsson Lönn S, Sundquist J, Sundquist K, Kendler KS	Disentangling Social Genetic from Rearing Environmental Effects for Alcohol Use Disorder Using Swedish National Data	31
Bart CP, Chat IK, Carroll AL, Armstrong CC, Nusslock R, Alloy LB	Decreased Prefrontal Responses to Monetary Rewards Is Predictive of Future Substance Use	32
Ingram WM, Weston C, Lu WD, Hodge C, Poler SM, Nahi F, Larson S	Factors Affecting Electroconvulsive Therapy Ictal Outcomes: Duration and Postictal Suppression	33
Paksarian D, Rudolph KE, James P, Mennitt DJ, Casey JA, Merikangas KR	Artificial Light at Night and Mental Disorders Among US Adolescents	34

Vadhan, NP, Madden, SP & Keilp, JG	Psychomotor Speed Is Inversely Related to Cocaine Use Amount: A Human Laboratory Study	35
Ditmars HL, Cuthbert KN, Logue MW, Reynolds CA, Toomey R, McKenzie RE, Kremen WS, Franz CE, Panizzon MS, Vandiver R, Lyons MJ	Patterns of Depression Symptoms in a 12-Year Longitudinal Study of Vietnam-Era Twin Veterans	36
Lewis CE, North CS	Patterns of Alcohol Consumption Over 21 Years Following Hospitalization for Alcohol Use Disorder	37
Newman BN, Crowell K	The Intersectionality of Criminality and Substance Use Self-Stigmas: Contributions to Relapse and Recidivism	38
Wang KT, Serper M	Longitudinal Assessment of Temporal Self Identity and Psychopathology	39
Wertz J, Israel S, Arseneault L, Bourassa KJ, Harrington H, Houts R, Poulton R, Richmond-Rakerd LS, Røysamb E, Moffitt TE, Caspi A	The Vital Personality and Healthy Aging: Replicated Life-Course Evidence About Measurement, Correlates, and Familial Transmission	40
Kaur N, Rutherford CG, Martins SS, Keyes KM	Associations Between Social Media Use and Substance Use Among U.S. 8th, 10th, and 12th Grade Students: Results from the 2018 Monitoring the Future Survey	41
Riehm KE, Thrul J, Barrington-Trimis JL, Kelleghan A, Mojtabai R, Leventhal AM	Prospective Association of Digital Media Use with Alcohol-Related Behaviors Among Adolescents	42
Zomick J, Zhengping J, Levitan SI, Phili A, Groves K, Hirschberg J, Serper M	Discriminating Psychiatric Disorders via Linguistic Analysis and Pronoun Usage on Reddit	43
Todaro, SM, Uhouse, SG, Morgano, JA, Bates, ME, Buckman, JF	Individual and Contextual Differences in Use and of Breathing-Based iPhone App Intervention in Women with SUD	44
Gastfriend E, Gastfriend D, Tse I	An Innovation Digital Intervention for Substance Use	45
Webb L, Clary L, Mendelson T	The Association of Electronic Bullying and Substance Use in Racial/Ethnic and Sexual Minority Youth	46

American Psychopathological Association Meeting Code of Conduct

The American Psychopathological Association (“APPA”) is dedicated to providing a safe and productive experience for all participants and attendees at all official APPA events regardless of sex, race, color, national origin, religion, age, physical or mental disability, perceived disability, ancestry, marital status, sexual orientation, or any other basis protected by laws. APPA does not tolerate discrimination or any form of prohibited harassment and is committed to enforcing this Code of Conduct (the “Code”) at its Annual Conference or at any other APPA event. As a professional society, the APPA is committed to providing an atmosphere that encourages the free expression and exchange of scientific and educational ideas. Furthermore, APPA upholds the philosophy of equal opportunity for and treatment of all conference or other meeting participants and staff in any venue.

2. Scope of Code

APPA requires compliance with the Code by all meeting participants, staff, guests, and vendors at all official APPA events, including the annual conference, committee meetings or other activities that are expressly sponsored or promoted by APPA, whether held in public or private facilities. This policy is an expression of APPA’s values and commitment to a safe and productive experience for all participants and attendees at its official events. This policy is not an acknowledgement, admission, or description of APPA’s legal obligations with respect to any of the subject matters addressed herein, nor does it create any such legal obligations.

3. Harassment Defined

Prohibited harassment includes verbal, physical, and visual conduct that creates an intimidating, offensive, or hostile environment. Harassing conduct can take many forms and includes, but is not limited to, the following: slurs, epithets, derogatory comments, insults, degrading or obscene words, jokes, demeaning statements, offensive gestures, or displaying derogatory or demeaning pictures, drawings, or cartoons based upon an individual’s sex, race, color, national origin, religion, age, physical or mental disability, perceived disability, ancestry, marital status, or sexual orientation.

Sexually harassing conduct in particular includes all of these prohibited actions, as well as other unwelcome conduct that is sexual in nature, such as unwanted sexual advances; lewd propositions or innuendos; leering; making sexual gestures; making sexually suggestive or graphic comments or engaging in inappropriate sexually-oriented conversation; displaying sexually suggestive objects, graphics, pictures, or posters, whether physically or over the Internet; making or using derogatory comments, epithets, slurs or jokes; the sexual touching or display of one’s own body; or unwanted physical touching or assault, as well as impeding or blocking movements.

Sexually harassing conduct can be by a person of either the same or opposite sex. It is a violation of this policy for males to sexually harass females or other males, and for females to sexually harass males or other females. Conduct that begins as consensual in nature may become harassment if one party withdraws his or her consent. Sexual or other harassment prohibited by this policy is unacceptable and will not be tolerated.

The above list of prohibited behaviors is not a complete rendering of what may be deemed sexual or other harassment prohibited by this policy. It is impossible to define every action or word that could be interpreted as harassment. However, APPA has a “zero tolerance” policy toward discrimination and all forms of harassment. APPA reserves the right to discipline meeting participants who engage in any inappropriate conduct, even if it is not specifically referred to or defined in this Code, or is not legally actionable as sexual or any other form of harassment.

4. Prohibited Conduct

Prohibited conduct at APPA meetings includes, but is not limited to:

- harassment based on sex, race, color, personal appearance, national origin, religion, age, physical disability, mental disability, perceived disability, ancestry, marital status, sexual orientation, or any other basis protected by federal or pertinent state laws;
- demeaning comments or harassment about a person's professional status, qualifications, or affiliations;
- sexual harassment, as defined in Section 3;
- abusive conduct that has the purpose or effect of unreasonably interfering with another person's ability to benefit from and enjoy or participate in the conference, including social events related to the conference sponsored by APPA;
- undue or excessive interruption of any event, speaker, or session; and
- violence or threats of violence.

5. Reporting an Incident

Meeting or conference participants or other individuals, who witness or experience inappropriate conduct at an APPA meeting, conference or other official APPA event, including but not limited to the prohibited conduct described above, should report such conduct immediately to the CEO of PMG, Sarah Timm at stimm@parthenonmgmt.com or (615) 324-2374. If the individual is uncomfortable reporting the conduct to the CEO of PMG for any reason, the individual may report the conduct to the APPA Secretary, Jo-Ann Donatelli at jo-ann_donatelli@brown.edu. Any individual reporting such conduct is not required or expected to discuss the concern with the alleged offender. Anyone experiencing or witnessing behavior at an APPA event that is an immediate or serious threat to the safety of those present, or to the public, is advised to locate a house phone and ask for security, or to otherwise contact the authorities for protection.

APPA cannot address claimed inappropriate conduct or harassment unless the claims are brought to the attention of APPA leadership. Meeting participants are encouraged to report any incidents of perceived violations of this policy as quickly as they can or otherwise feel safe doing.

APPA is committed to taking reasonable steps to prevent harassment and other prohibited conduct at its meetings and will make reasonable efforts to promptly and completely address and correct any prohibited conduct that may occur at an official APPA event. APPA will keep any investigation of an alleged violation of this policy as confidential as possible.

APPA can only investigate situations that arise at APPA meetings or other APPA-sponsored events. If a meeting participant experiences inappropriate conduct or harassment at the participant's own or another institution, at a place of work, at a research facility, or online but not via APPA-sponsored channels that individual should contact the appropriate person or department responsible for such things at that particular institution, facility or medium.

6. Investigation

APPA will promptly and impartially investigate the facts and circumstances of any claim of inappropriate conduct or harassment under this policy. APPA will make every effort to keep the reporting individual's concerns confidential and will not deliberately share personal information, other than as necessary to carry out the purpose of investigation. While complete confidentiality cannot be guaranteed, APPA will keep the investigation and its findings as confidential as possible under the circumstances. During an investigation, APPA or a designated independent consultant subject to obligations of confidentiality, generally will do the following (as necessary) to make a determination as to appropriate action:

- document the nature of the complaint;
- interview the complainant;
- conduct further interviews as necessary, such as with witnesses and, at an appropriate time, the alleged offender;
- document the APPA's findings regarding the complaint;

- document recommended follow-up actions and remedies, if warranted; and
- inform the complainant of the basic nature of the APPA's findings.

The APPA will attempt to investigate any complaint or report of a violation of this policy in a prompt and timely manner. Upon completion of the investigation, APPA will take appropriate corrective measures against any person who has engaged in conduct prohibited by this policy, if APPA determines such measures are necessary. Such remedial action may include, but is not limited to, the items listed below in Section 7.

7. Disciplinary Action

If APPA determines that an individual has engaged in prohibited conduct, APPA shall determine the appropriate action to be taken, which may include, but is not limited to:

- private reprimand;
- removal from a meeting or the conference without warning or refund;
- implementation of conditions upon attendance at future APPA Conferences;
- restriction from attendance at future APPA Conferences; or
- expulsion from membership of APPA.

APPA may, but is not required to, report any incident to proper authorities, including but not limited to law enforcement. APPA will do so if, in its sole discretion, such reporting is advisable or necessary. If APPA determines that an individual has engaged in prohibited conduct at an APPA meeting, and such individual is an APPA member, APPA may take disciplinary measures. Nothing in this policy shall restrict or discourage any individual who experiences or is the target of conduct prohibited by this policy from reporting such conduct to the authorities, to the extent he or she deems such a report advisable or necessary.

8. Retaliation Is Not Tolerated

Retaliation for complaints of inappropriate conduct or harassment are also considered harassment and will not be tolerated. Retaliatory behavior in connection with APPA meetings will be investigated in a similar manner to initial complaints.

Continuing Education

AMA and APA credits will be available for the meeting. There is no charge to apply for credits. All attendees wishing to apply for credits will be required to complete an online evaluation of the meeting prior to applying for credits. The online evaluation and credit application will be available at the conclusion of the meeting.

Satisfactory Completion

Learners must complete an evaluation form to receive a certificate of completion. Your chosen sessions must be attended in their entirety. Partial credit of individual sessions is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.

Physicians



JOINTLY ACCREDITED PROVIDER™
INTERPROFESSIONAL CONTINUING EDUCATION

In support of improving patient care, this activity has been planned and implemented by Amedco LLC and the American PsychoPathological Association (APPA). Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation Statement – Amedco LLC designates this live activity for a maximum of 13.25 *AMA PRA Category 1 Credits*™. Learners should claim only the credit commensurate with the extent of their participation in the activity.

Psychologists



This course is co-sponsored by Amedco and APPA. Amedco is approved by the American Psychological Association to sponsor continuing education for psychologists. Amedco maintains responsibility for this program and its content. Maximum of 13.25 hours.

The following state boards accept courses from APA providers for Counselors: AK, AL, AR, AZ, CA, CO, CT, DC, DE, FL, GA, HI, IA, ID, IL, IN, KS, MD, ME, MO, NC, ND, NH, NE, NJ, NM, NV, OK, OR, PA, RI, SC, SD, TN, TX, UT, VA, WI, WY

MI: No CE requirements

The following state boards accept courses from APA providers for MFTs: AK, AR, AZ, CA, CO, CT, DE, FL, GA, IA, ID, IN, KS, MD, ME, MO, NE, NC, NH, NJ, NM, NV, OK, OR, PA, RI, SC, SD, TN, TX, UT, VA, WA, WI, WY

The following state boards accept courses from APA providers for Addictions Professionals: AK, AR, CO, CT, DC, DE, GA, IA, IN, KS, LA, MD, MO, MT, NC, ND, NE, NJ, NM, NY (outstate held), OK, OR, SC,

UT, WA, WI, WY

MA / MFTs: Participants can self-submit courses not approved by the MAMFT board for review.

The following state boards accept courses from APA providers for Social Workers: AK, AR, AZ, CA, CO, DE, FL, GA, ID, IN, KY, ME, MN, MO, NE, NH, NM, OR, PA, VT, WI, WY

Physician Assistants

AAPA accepts *AMA PRA Category 1 Credit(s)*TM for the PRA from organizations accredited by ACCME. Maximum of 13.25 hours.

Nurse Practitioners

The American Association of Nurse Practitioners (AANP) recognizes the Accreditation Council for Continuing Medical Education (ACCME) and the American Nurses Credentialing Center (ANCC) as approved accreditors and allow reciprocity for AANPCP continuing education credit. Maximum of 13.25 hours.

Learning Objectives

After participating in this educational activity, the attendee should:

1. Understand what is known about risk factors for substance use and substance use disorders (alcohol and drugs), from the neurobiological to macro-societal level, and what remains to be learned.
2. Understand what is known about the medical, psychiatric, cognitive and psychosocial consequences of substance use and substance use disorders, and what remains to be learned.
3. Understand what is known about the diagnosis and treatment of alcohol and drug use disorders, including the effectiveness of pharmacological and behavioral treatments, and what remains to be learned.

Target Audience

The primary audience for the meeting is researchers and clinicians. Researchers will be in the fields of psychiatry, psychology, epidemiology, neuroscience, economics, genetics and general medicine. Clinicians will include psychiatrists, psychologists, and social workers.

For activity questions, please contact registration@appassn.org.

Learning Objectives

Session 1: The View From the National Institutes of Health

- I understand the heuristic value of the 3-stage addiction cycle for diagnosis, prevention and treatment of alcohol use disorder.
- I understand recent breakthroughs in the molecular and neurocircuitry mechanisms that lead to and maintain alcohol use disorder.
- I recognize 5 salient emerging issues in Alcohol Research: women and alcohol, pain and alcohol, sleep and alcohol, high intensity drinking.
- I can describe increasing trends in vaping of nicotine and/or marijuana among 8th, 10th and 12th graders.
- I can describe current drug use trends among adolescents in the U.S.

Session 2: Policy

- I understand current evidence on the impact of state drug policies on the opioid overdose epidemic.
- I can appreciate how a for-profit cannabis legalization model dramatically alters supply, demand, and patterns of cannabis use.

Session 3: Epidemiology

- I was provided an overview of current trends in substance use and substance use disorders in adolescence and adulthood, with a focus on what birth cohorts are at higher risk for substance use across the lifecourse.
- I am able to identify childhood risks and postulate intergenerational factors relevant for the development of substance abuse in high risk groups.
- I understand racial/ethnic disparities in psychiatric disorders and substance use disorders.
- I learned how to apply a health equity lens to develop solutions to reduce disparities.

Session 4: Neurofunctioning and Genetics

- I can describe functional disturbances in brain reward circuits in patients with alcohol use disorders or at increased genetic risk for alcoholism, highlighting potential roles of disturbances in dopamine and glutamate signaling.
- I am able to identify chronic drug related adaptations in brain and peripheral stress pathways that contribute to high drug craving, negative affect and relapse risk in addiction and sex differences in the adaptive biology underlying these associations.
- I learned of the current state-of-the-art regarding the genetics of alcohol use disorders, based on studies from the Million Veteran Program.
- I understand the design, objectives and methods of the Adolescent Brain and Cognitive Development large scale study of youth and means to access the data currently available through NDA.

Session 5: Measurement: Diagnosis, Outcomes

- I can characterize at least two new areas of non-traditional outcome measures that are being considered for studies of SUDs.
- I can describe at least one strength and one limitation for the use of each of these new areas of non-traditional outcome measures for SUD studies.
- I can identify at least two traditional outcome measures used in studies of treatments for substance use disorders (SUDs).

Session 6: Exposure Consequences I

- I understand the causal relationship between cannabis use and psychosis.
- I can describe the relative and absolute risk of overdose and suicide mortality for individuals with substance use disorders.
- I understand the risk factors for suicide and suicide attempts among persons with substance abuse diagnoses.

Session 7: Exposure Consequences II

- I can discuss the prevalence of FASD in four regions of the United States.
- I learned about the prevailing theories of the role of alcohol responses in the development of alcohol use disorder (AUD) and the methods used to test these models in humans across the spectrum of light, heavy and AUD drinkers.
- I understand factors that might affect the likelihood of naloxone use among drug users.
- I understand recent rates of Cannabis Use Disorder (CUD) in the U.S., characteristics of the disorder, and research on the development of pharmacologic approaches to improve the treatment of CUD.

Session 8: Evidence-Based Treatments and Their Dissemination

- I can recite the medications approved by the Food and Drug Administration for the treatment of Alcohol Use Disorder.

- I received an update on recently approved medications for opioid use disorders and recent high impact publications.
- I understand the major form of evidence based behavioral therapies and their level of support delivered alone or with pharmacotherapy for substance use disorders.
- I understand national screening recommendations for unhealthy alcohol and other drug use, and whether or not the evidence supports efficacy of the practice for improving any outcomes.

2020 APPA Annual Meeting Disclosures

Program Committee

- **Hasin, Deborah** – InventivHealth (Research Grant, Principal Investigator)
- **DePaulo, J Raymond** – Myriad_Assurex (Unpaid Consultant); CVS (Stock Shareholder)

The following Program Committee members have nothing to disclose:

Gilman, Stephen
Lyons, Michael
Merikangas, Kathleen
Potash, James
Santangelo, Susan
Stone, William
Wilson, Helen

Speakers

- **Carroll, Kathleen**- CBT4CBT (Consultant)
- **Comer, Sandra** – Alkermes (Research Grant, Principal Investigator); Corbus (Research Grant, Principal Investigator); Janssen (Research Grant, Principal Investigator); Intracellular Therapies (Research Grant, Principal Investigator); Go Medical (Other Financial or Material Support); Lyndra (Research Grant, Principal Investigator); Mallinckrodt (Consultant); Epiodyne (Consultant); Opiant (Scientific/Medical Advisory Board Member); Sun Pharma (Consultant); Nektar (Consultant); Otsuka (Consultant)
- **Gelernter, Joel** – Patent Application (Patent Holder)
- **Hasin, Deborah** – InventivHealth (Research Grant, Principal Investigator)
- **Keyes, Katherine** – Plaintiffs in the multi-district opioid litigation (Consultant)
- **Kranzler, Henry** – American Society of Clinical Psychopharmacology's alcohol clinical trials initiative (Consultant)
- **Krystal, John** – Janssen Pharmaceuticals (Consultant); Novartis (Scientific/Medical Advisory Board Member); Biohaven Pharmaceuticals (Stock Shareholder); Sage Pharmaceuticals (Stock Shareholder); Spring Care, Inc. (Stock Shareholder); EpVario (Stock Shareholder); BlackThorn Therapeutics (Stock Shareholder); Inheris Biopharma, Inc. (Scientific/Medical Advisory Board Member); Terran Life Sciences (Stock Shareholder)
- **Nunes, Edward** – Braeburn (Research Grant, Principal Investigator); Indivior (Research Grant, Principal Investigator); Alkermes (Scientific/Medical Advisory Board Member)
- **O'Malley, Stephanie** – ACTIVE Workgroup supported by Alkermes, Ethypharm, Lundbeck, Otsuka, and Mitsubishi (Work Group Member); Amygdala (Unpaid Consultant); Alkermes (Scientific/Medical Advisory Board Member); Opiant (Scientific/Medical Advisory Board Member)
- **Saitz, Richard** – Alkermes (Research Grant, Principal Investigator)
- **Sinha, Rajita** – Embera Neurotherapeutics (Scientific/Medical Advisory Board Member)
- **Strain, Eric** – Analgesic Solutions (Scientific/Medical Advisory Board Member); Alkermes (Research Grant, Principal Investigator); Caron (Scientific/Medical Advisory Board Member); Indivior Pharmaceuticals (Consultant); The Oak Group (Scientific/Medical Advisory Board Member); Otsuka Pharmaceuticals (Consultant); Pinney Associates (Scientific/Medical Advisory Board Member)

2020 APPA Annual Meeting Disclosures

The following speakers have nothing to disclose:

Bohnert, Amy
Branas, Charles
Breslau, Joshua
Budney, Alan
Caulkins, Jonathan
Cerda, Magdalena
Des Jarlais, Don
Duarte, Cristiane
Furr-Holden, Debra
Gradus, Jaimie
Haney, Margaret

Harkavy-Friedman, Jill
Heitzeg, Mary
King, Andrea
Koob, George
Lee, Joshua
Martinez, Diana M.
Martins, Silvia
May, Philip
Murray, Robin
Rotrosen, John
Volkow, Nora

APPA

AMERICAN PSYCHOPATHOLOGICAL ASSOCIATION, INC.

1910-2020

INFORMATION ITEMS

For those at the meeting who need information on local resources for child and family care, please contact Ms. Claire Walsh (Claire.Walsh@nyspi.columbia.edu), who can provide this information on request.

SAVE THE DATE!

2021 Annual Meeting of the
American PsychoPathological Association
March 4-6, 2021

New York City, NY
Crowne Plaza Times Square Manhattan

appassn.org

APPA

Save the Date